All Blogs
Feb 13, 2025
Agiliti Launches Essentia; KUBTEC Introduces PICASSO Plus; FDA Clears Neuvotion’s NeuStim™ for Non-Invasive Hand Stimulation in Stroke & SCI Patients; Ibex Medical Analytics Achieves Milestone with FDA 510(k) Clearance; BlueWind Medical Reports Strong Two-Year Outcomes for Revi® System in Peer-Reviewed Study; Reprieve Cardiovascular’s FASTR Pilot Trial Shows Positive Outcomes, FDA Approves IDE for Next Phase
Agiliti Launched Essentia, an Innovative Multi-Acuity Hospital Bed that Helps Lower Patient Risk and Accelerate Mobility On February 11, 2025, Agiliti, a prominent manufacturer and provider of medical device solutions for the U.S. healthcare industry, introduced Essentia™, a versatile multi-acuity bed fram...
Read More...
Feb 12, 2025
Medication Management Systems: The Key to Optimizing Pharmaceutical Care
Medication management is a critical aspect of healthcare that ensures patients receive the right medication, in the correct dosage, at the appropriate time, and for the intended purpose. With increasing complexity in treatment regimens and rising incidences of medication errors, an effective medication management s...
Read More...
Feb 11, 2025
Immix Bio’s NXC-201 Gets FDA RMAT for AL Amyloidosis; Biodexa’s eRapa Wins Fast Track for Familial Adenomatous Polyposis; AbbVie’s EMBLAVEO Approved for Complicated Intra-Abdominal Infections; Insmed’s Brensocatib Gains Priority Review for Bronchiectasis; Aro Bio’s ABX1100 IND Cleared for Pompe Disease
Immix Biopharma's NXC-201 Receives FDA RMAT Designation for Relapsed/Refractory AL Amyloidosis Immix Biopharma has received the FDA’s RMAT (Regenerative Medicine Advanced Therapy) designation for NXC-201, a sterically optimized CAR-T therapy for relapsed/refractory AL amyloidosis. The designation is granted to r...
Read More...
Feb 10, 2025
Acute Myeloid Leukemia: The Battle, The Breakthroughs, The Future
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer that originates in the bone marrow—the soft, inner part of bones where blood cells are produced—and swiftly moves into the blood. Globally, the burden of AML has been increasing over the past few decades. The exact cause of AML remains elusive, but severa...
Read More...
Feb 07, 2025
10 Game-Changing Acute Myeloid Leukemia Drugs Revolutionizing Treatment
Acute Myeloid Leukemia (AML) is a fast-moving and aggressive cancer that demands timely and effective treatment. With the current acute myeloid leukemia therapies showing limited success for many patients, the focus has shifted to breakthrough AML drugs that are redefining the treatment landscape. From innovative s...
Read More...
Feb 06, 2025
Bioretec Ltd. Gains CE Mark for RemeOs™ Trauma Screw; HoneyNaps’ AI Sleep Diagnostic Software Achieves Recognition as the 73rd and 74th Innovative Medical Devices by South Korea’s MFDS; Movano Health Advances Clinical Trials for Innovative Non-Cuff Blood Pressure Monitor; IRB Approves PathMaker Neurosystems’ MyoRegulator® ALS Study; Aspen Medical Products Closes Deal to Acquire Advanced Orthopaedics; Surmodics Achieves Early Clinical Success with Pounce™ XL Thrombectomy System
Bioretec Ltd. Secured CE Mark Approval for RemeOs™ Trauma Screw, Enabling European Market Launch On January 31, 2025, Bioretec Ltd., a leader in absorbable orthopedic implants, successfully completed the CE mark approval process and began the commercialization of its RemeOs™ Trauma Screw product portfolio ...
Read More...
Feb 05, 2025
Healthcare Asset Management: Optimizing Resources for Better Patient Care
In the healthcare industry, efficient management of resources is vital to ensure that patient care is delivered smoothly and cost-effectively. Healthcare asset management refers to the systematic process of managing medical equipment, devices, and resources to ensure that they are utilized, maintained, and tracked ...
Read More...
Feb 04, 2025
AstraZeneca Scraps £450M UK Vaccine Factory; FDA Approves First Non-Opioid Pain Reliever JOURNAVX in 20+ Years; Axsome’s SYMBRAVO Wins FDA Nod for Migraine; March Biosciences’ MB-105 Gains FDA Orphan Status for T-Cell Lymphoma; Saol’s SL1009 NDA Accepted for Pyruvate Dehydrogenase Complex Deficiency
AstraZeneca Scraps £450M Vaccine Factory in UK, Dealing a Blow to Reeves AstraZeneca has withdrawn its planned £450 million investment to expand a vaccine manufacturing facility in Liverpool, citing reduced financial support from the new Labour government. Initially announced in the previous Conservative governm...
Read More...
Feb 03, 2025
OZEMPIC’s New Approval Cements Novo’s Lead in GLP-1 Market
The recent approval of OZEMPIC reinforces the growing trend of GLP-1 drugs being used for conditions beyond diabetes and weight loss. Novo Nordisk’s blockbuster GLP-1 medication, OZEMPIC, has secured another label expansion, as the FDA has now approved it for treating chronic kidney disease. The approval for chr...
Read More...
Jan 31, 2025
Interleukin-2-targeting Therapies: Journey from Bench to Bedside
Expected data readouts in 2025, filling the unmet need, and estimated market opportunity in Oncology, Immunological and Neurodegenerative Diseases In the evolving landscape of immunotherapy, Interleukin-2 (IL-2) therapies have carved a niche, particularly in the treatment of metastatic melanoma, metastatic renal...
Read More...